Screener
Eli Lilly LLY Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Repayments of long-term debt | (1,623) | (778) |
| Purchases of common stock | (3,957) | (1,892) |
| Other financing activities, net | (595) | (717) |
| Net Cash Provided by Financing Activities | 4,956 | 135 |
| Effect of exchange rate changes on cash and cash equivalents | 15 | 407 |
| Net increase in cash and cash equivalents | 1,682 | 108 |
| Cash and cash equivalents at January 1 | 7,268 | 3,268 |
| Cash and Cash Equivalents at June 30 | $8,950 | $3,376 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's cash and cash equivalents, end of period?
- Eli Lilly (LLY) reported cash and cash equivalents, end of period of $8.95B in Q2 2026.
- How has Eli Lilly's cash and cash equivalents, end of period changed year-over-year?
- Eli Lilly's cash and cash equivalents, end of period increased by 165.1% year-over-year, from $3.38B to $8.95B.
- What is the long-term trend for Eli Lilly's cash and cash equivalents, end of period?
- Over 5 years (2020 to 2025), Eli Lilly's cash and cash equivalents, end of period has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.
- What does cash and cash equivalents, end of period mean?
- Cash and cash equivalents, end of period
Ask your AI about Eli Lilly's cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude